213 related articles for article (PubMed ID: 6395527)
21. [Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine].
Saletu B; Grünberger J; Anderer P; Chwatal K
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():45-55. PubMed ID: 1683340
[TBL] [Abstract][Full Text] [Related]
22. Pharmaco-EEG and psychometric studies with a novel selective benzodiazepine agonist/antagonist Ro 23-0364.
Saletu B; Grünberger J; Cepko H
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):421-37. PubMed ID: 2888736
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of encephalotropic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry.
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):362-73. PubMed ID: 3525428
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
[TBL] [Abstract][Full Text] [Related]
25. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E
Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
[TBL] [Abstract][Full Text] [Related]
26. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
Nobuhara K
Seishin Shinkeigaku Zasshi; 1993; 95(5):392-416. PubMed ID: 8356168
[TBL] [Abstract][Full Text] [Related]
27. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
Saletu B; Anderer P; Wolzt M; Nosiska D; Assandri A; Noseda E; Nannipieri F; Saletu-Zyhlarz GM
Neuropsychobiology; 2009; 59(2):110-22. PubMed ID: 19365151
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.
Saletu-Zyhlarz GM; Anderer P; Wolzt M; Semlitsch HV; Assandri A; Nessi P; Nannipieri F; Rosini S; Saletu B
Neuropsychobiology; 2009; 59(2):100-9. PubMed ID: 19365150
[TBL] [Abstract][Full Text] [Related]
29. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment.
Semlitsch HV; Anderer P; Saletu B; Hochmayer I
Neuropsychobiology; 1990-1991; 24(1):49-56. PubMed ID: 2132641
[TBL] [Abstract][Full Text] [Related]
30. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
[TBL] [Abstract][Full Text] [Related]
31. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
Saletu B; Grünberger J; Linzmayer L
Arch Gerontol Geriatr; 1986 Oct; 5(3):165-81. PubMed ID: 3541816
[TBL] [Abstract][Full Text] [Related]
32. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses.
Saletu B; Grünberger J; Volavka J; Berner P
Arzneimittelforschung; 1979; 29(4):700-4. PubMed ID: 582772
[TBL] [Abstract][Full Text] [Related]
33. [Analytic study on EEG features of aging with/without psychiatric disorders: focussing at the alterations in the EEGs of the healthy, depressive and demented elderlies].
Saito N
Seishin Shinkeigaku Zasshi; 1995; 97(10):801-24. PubMed ID: 8552725
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of pharmacodynamic properties of psychotropic drugs: quanitative EEG, psychometric and blood level investigations in normals and patients.
Saletu B; Grünberger J
Pharmakopsychiatr Neuropsychopharmakol; 1979 Jan; 12(1):45-58. PubMed ID: 419165
[TBL] [Abstract][Full Text] [Related]
35. [Oral actovegin therapy in cerebrovascular insufficiency. Studies on the therapeutic value of actovegin forte dragees in elderly patients with advanced cerebrovascular insufficiency].
Kopp H
Fortschr Med; 1979 Feb; 97(7):307-12. PubMed ID: 437665
[TBL] [Abstract][Full Text] [Related]
36. [Demonstration of bencyclane effects in a clinico-pharmacologic vigilance model].
Herrmann WM; Kern U
Z Gerontol; 1984; 17(5):261-70. PubMed ID: 6395526
[TBL] [Abstract][Full Text] [Related]
37. CNS pharmacology and clinical therapeutic effects of oxiracetam.
Itil TM; Menon GN; Songar A; Itil KZ
Clin Neuropharmacol; 1986; 9 Suppl 3():S70-2. PubMed ID: 3594458
[TBL] [Abstract][Full Text] [Related]
38. Classification and determination of cerebral biovailability of psychotropic drugs by quantitative "pharmaco-EEG" and psychometric investigations (studies with AX-A411-BS).
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):449-59. PubMed ID: 21853
[TBL] [Abstract][Full Text] [Related]
39. Classification and assessment of cerebral bioavailability of lopirazepam (D-12524) by quantitative EEG and psychometric analysis.
Saletu B; Grünberger J; Linzmayer L; Stadler R
Arzneimittelforschung; 1980; 30(3):513-8. PubMed ID: 6104496
[TBL] [Abstract][Full Text] [Related]
40. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
